Monoclonal Antibody Process Development Using Medium Concentrates

• Published in: Biotechnology progress Vol. 10; no. 1; pp. 87 - 96
• Main Authors: Bibila, Theodora A., Ranucci, Colette S., Glazomitsky, Konstantin, Buckland, Barry C., Aunins, John G.
• Format: Journal Article
• Language: English
• Published: USA American Chemical Society 01-01-1994; American Institute of Chemical Engineers
• Subjects: Amino Acids - metabolism; Ammonia - metabolism; Animal cells; Animals; Antibodies, Monoclonal - biosynthesis; Biological and medical sciences; Biotechnology; Cell hybridization, cell fusion, hybridomas; Cell Line; Culture Media; Eukaryotic cell cultures; Fundamental and applied biological sciences. Psychology; Glucose - metabolism; Lactates - metabolism; Lactic Acid; Methods. Procedures. Technologies; Mice; Osmolar Concentration; Performance evaluation; Culture medium; Cell culture; Purification; Metabolite; Rodentia; Monoclonal antibody; Myeloma; Optimization; Characterization; Vertebrata; Mammalia; Mouse; Animal; Nutrient; Semicontinuous
• ISSN: 8756-7938; 1520-6033
• DOI: 10.1021/bp00025a011

A fed‐batch process using concentrated medium was evaluated for its ability to improve cell culture longevity and final monoclonal antibody (MAb) titers for two monoclonal antibody producing cell lines. It was found to result in up to 7‐fold increases in final antibody titers compared to batch culture controls. Although the development of cell line specific fed‐batch protocols is critical to the development of cost‐efficient largescale production processes, the use of complete medium concentrates provided us with a quick and simple method for producing large quantities of antibodies in the early stages of process development, thus accelerating early work on purification process development, analytical development, biochemical characterization, and safety studies. Insights gained from the concentrated medium fed‐batch approach were valuable for the development of refined, cell line specific feeding strategies yielding final MAb titers on the order of 1–2 g/L. Process development data on the effects of inhibitory growth byproducts, medium osmolarity, and the mode of nutrient feed addition on culture longevity and MAb production and information on culture metabolic behavior were successfully incorporated in the development of the optimized fed‐batch protocols.